Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products, including its flagship C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Type
Public
HQ
Omaha, US
Founded
1997
Employees
150 (est)
Transgenomic was founded in 1997 and is headquartered in Omaha, US

Transgenomic Locations

Omaha, US
New Haven, US

Transgenomic Metrics

Transgenomic Summary

Market capitalization

$5.95 M

Closing share price

$0.2
Transgenomic's latest market capitalization is $5.95 M.

Transgenomic Market Value History

Transgenomic Online Presence

Transgenomic Company Life

You may also be interested in